Status:
COMPLETED
Topical Menthol Application in Chemotherapy-Related Peripheral Neuropathy in Patients With Breast Cancer
Lead Sponsor:
Necmettin Erbakan University
Conditions:
Breast Cancer
Peripheral Neuropathies
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Peripheral neuropathy resulting from chemotherapy is a problem that concerns not only the individual but also their relatives and all healthcare personnel responsible for care. Studies to be carried o...
Detailed Description
Introduction and Aim: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common side effects of chemotherapeutic agents. CIPN is a frequently dose-limiting neurotoxicity that causes ...
Eligibility Criteria
Inclusion
- Patients who received at least two cycles of chemotherapy
- Patients aged 18 and over
- Women who received the paclitaxel chemotherapy protocol will be included.
Exclusion
- Those with open wounds and edema on their hands and feet
- Patients with diabetes mellitus and peripheral neuropathy due to autoimmune disease
- Use complementary and alternative treatment methods to prevent peripheral neuropathy throughout the treatment process.
- Those who are allergic to topical menthol to be used in the study will be excluded from the study.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05429814
Start Date
July 1 2022
End Date
April 1 2023
Last Update
April 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Necmettin Erbakan University
Konya, Meram, Turkey (Türkiye), 42090